Distribution of subsequent primary invasive melanomas following a first primary invasive OR in situ Melanoma Queensland, Australia, 1982-2010

JAMA Dermatology

Volumn 150, Issue 5, 2014, Pages 526-534

  Youlden, Danny R ^a   Youl, Philippa H ^a   Soyer, H Peter ^b   Aitken, Joanne F ^a   Baade, Peter D ^a  

^a CANCER COUNCIL QUEENSLAND   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; AUSTRALIA; CANCER DIAGNOSIS; CANCER GROWTH; CANCER INCIDENCE; CANCER SURVIVAL; CARCINOMA IN SITU; COHORT ANALYSIS; DISEASE DURATION; FEMALE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; MELANOMA METASTASIS; ONSET AGE; PRIMARY TUMOR; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE;

ADULT; AGE DISTRIBUTION; AGED; BIOPSY, NEEDLE; CARCINOMA IN SITU; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENCE; MALE; MELANOMA; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; QUEENSLAND; REGISTRIES; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX DISTRIBUTION; SKIN NEOPLASMS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 84901044340     PISSN: 21686068     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamadermatol.2013.9852     Document Type: Article

References (35)

1. Green A, Siskind V. Geographical distribution of cutaneous melanoma in Queensland. Med J Aust. 1983;1(9):407-410.
2. Coory M, Baade P, Aitken J, Smithers M, McLeod GR, Ring I. Trends for in situ and invasive melanoma in Queensland, Australia, 1982-2002. Cancer Causes Control. 2006;17(1):21-27.
3. Queensland Cancer Registry, Cancer Council Queensland, Queensland Health. Cancer in Queensland, 1982-2010. Brisbane, Australia: Cancer Council Queensland; 2013.
4. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and MortalityWorldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; 2010. http://globocan. iarc.fr. Accessed June 4, 2013.
5. Karahalios E, English D, Thursfield V, Simpson J, Farrugia H, Giles G. Second Primary Cancers in Victoria. Melbourne, Australia: Cancer Council Victoria; 2009.
6. Youlden DR, Baade PD. The relative risk of second primary cancers in Queensland, Australia: a retrospective cohort study. BMC Cancer. 2011;11:83. doi:10.1186/1471-2407-11-83.
7. Giles G, Staples M, McCredie M, Coates M. Multiple primary melanomas: an analysis of cancer registry data from Victoria and New SouthWales. Melanoma Res. 1995;5(6):433-438.
8. Gillgren P, Brattström G, Frisell J, Palmgren J, Ringborg U, Hansson J. Body site of cutaneous malignant melanoma-A study on patients with hereditary and multiple sporadic tumours. Melanoma Res. 2003;13(3):279-286.
9. McCaul KA, Fritschi L, Baade P, Coory M. The incidence of second primary invasive melanoma in Queensland, 1982-2003. Cancer Causes Control. 2008;19(5):451-458.
10. Balamurugan A, Rees JR, Kosary C, Rim SH, Li J, Stewart SL. Subsequent primary cancers among men and women with in situ and invasive melanoma of the skin. J AmAcad Dermatol. 2011;65(5) (suppl 1):S69-S77.
11. Howe HL, ed. A Review of the Definition for Multiple Primary Cancers in the United States. Springfield, IL: North American Association of Central Cancer Registries; 2003.
12. Curtis RE, Freedman MF, Ron E, et al, eds. New Malignancies Among Cancer Survivors: SEER Cancer Registries, 1973-2000. Bethesda, MD: National Cancer Institute; 2006. National Institutes of Health Publication No. 05-5302.
13. Breslow NE, Day NE. The Design and Analysis of Cohort Studies. Lyon, France: International Agency for Research on Cancer; 1987. Statistical Methods in Cancer Research; vol 2. International Agency for Research on Cancer Scientific Publication No. 82.
14. Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
15. Dalle S, Poulalhon N, Debarbieux S, et al. Tracking of second primary melanomas in vemurafenib-treated patients. JAMA Dermatol. 2013;149(4):488-490.
16. Zimmer L, Hillen U, Livingstone E, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol. 2012;30(19):2375-2383.
17. Dalle S, Poulalhon N, Thomas L. Vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;365(15):1448-1450.
18. Haenssle HA, Kraus SL, Brehmer F, et al. Dynamic changes in nevi of a patient with melanoma treated with vemurafenib: importance of sequential dermoscopy. Arch Dermatol. 2012;148(10):1183-1185.
19. Welch HG, Woloshin S, Schwartz LM. Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ. 2005;331(7515):481. doi:10.1136/bmj.38516.649537. E0.
20. Glusac EJ. The melanoma "epidemic", a dermatopathologist's perspective. J Cutan Pathol. 2011;38(3):264-267.
21. Weyers W. The "epidemic" of melanoma between under- and overdiagnosis. J Cutan Pathol. 2012;39(1):9-16.
22. Fields RC, Coit DG. Evidence-based follow-up for the patient with melanoma. Surg Oncol Clin N Am. 2011;20(1):181-200.
23. Australian Cancer Network Melanoma Guidelines RevisionWorking Party. Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand. Sydney, Australia: Cancer Council Australia, Australian Cancer Network and New Zealand Guidelines Group; 2008.
24. Dummer R, Hauschild A, Guggenheim M, Jost L, Pentheroudakis G; ESMO GuidelinesWorking Group. Melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 (suppl 5):v194-v197.
25. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines). Melanoma V2. 2010. http://www.nccn.org/ professionals/physician-gls/f-guidelines.asp. Accessed October 18, 2013.
26. McPherson M, Elwood M, English DR, Baade PD, Youl PH, Aitken JF. Presentation and detection of invasive melanoma in a high-risk population. J AmAcad Dermatol. 2006;54(5):783-792.
27. Francken AB, Shaw HM, Accortt NA, Soong SJ, Hoekstra HJ, Thompson JF. Detection of first relapse in cutaneous melanoma patients: implications for the formulation of evidence-based follow-up guidelines. Ann Surg Oncol. 2007;14(6):1924-1933.
28. Brobeil A, Rapaport D, Wells K, et al. Multiple primary melanomas: implications for screening and follow-up programs for melanoma. Ann Surg Oncol. 1997;4(1):19-23.
29. Garbe C, Paul A, Kohler-Späth H, et al. Prospective evaluation of a follow-up schedule in cutaneous melanoma patients: recommendations for an effective follow-up strategy. J Clin Oncol. 2003;21(3):520-529.
30. Kricker A, Armstrong BK, Goumas C, et al; GEM Study Group. Survival for patients with single and multiple primary melanomas: the genes, environment, and melanoma study. JAMA Dermatol. 2013;149(8):921-927.
31. Doubrovsky A, Menzies SW. Enhanced survival in patients with multiple primary melanoma. Arch Dermatol. 2003;139(8):1013-1018.
32. Wassberg C, Thörn M, Yuen J, Ringborg U, Hakulinen T. Second primary cancers in patients with cutaneous malignant melanoma: a population-based study in Sweden. Br J Cancer. 1996;73(2):255-259.
33. Levi F, La Vecchia C, Randimbison L, Te VC, Erler G. Incidence of invasive cancers following cutaneous malignant melanoma. Int J Cancer. 1997;72(5):776-779.
34. Di Fronzo LA, Wanek LA, Elashoff R, Morton DL. Increased incidence of second primary melanoma in patients with a previous cutaneous melanoma. Ann Surg Oncol. 1999;6(7):705-711.
35. Hayward NK. Genetics of melanoma predisposition. Oncogene. 2003;22(20):3053-3062.